Squarepoint
NRIX icon

Squarepoint’s Nurix Therapeutics NRIX Stock Holding History

Squarepoint’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.48M Buy
+224,535
New +$3.72M ﹤0.01% 1770
2025
Q4 		– Sell
-28,784
Closed -$266K – 4687
2025
Q3 		$266K Sell
28,784
-47,688
-62% -$495K ﹤0.01% 3766
2025
Q2 		$871K Sell
76,472
-8,154
-10% -$88.1K ﹤0.01% 2786
2025
Q1 		$1.01M Buy
84,626
+7,992
+10% +$134K ﹤0.01% 2653
2024
Q4 		$1.44M Buy
76,634
+9,354
+14% +$214K ﹤0.01% 2721
2024
Q3 		$1.51M Buy
67,280
+38,496
+134% +$872K ﹤0.01% 2280
2024
Q2 		$601K Buy
+28,784
New +$448K ﹤0.01% 2936
2022
Q2 		– Sell
-20,516
Closed -$287K – 3217
2022
Q1 		$287K Buy
20,516
+4,370
+27% +$77.6K ﹤0.01% 2307
2021
Q4 		$467K Buy
+16,146
New +$489K ﹤0.01% 2181
2021
Q3 		– Sell
-10,558
Closed -$280K – 3256
2021
Q2 		$280K Sell
10,558
-5,250
-33% -$154K ﹤0.01% 2589
2021
Q1 		$491K Buy
+15,808
New +$598K ﹤0.01% 2043

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Squarepoint's NRIX Position: Q1 2026 in Review

Squarepoint opened a new position in Nurix Therapeutics (NRIX) in Q1 2026: 224,535 shares worth $3.48M. The stake represents ﹤0.01% of the portfolio and ranks #1770 among its holdings. This is a return to the name: Squarepoint previously reported a position in NRIX as recently as Q3 2025.

Squarepoint first reported a position in NRIX in Q1 2021 and has held it in 11 quarters since. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Squarepoint held 224,535 shares of Nurix Therapeutics worth $3.48M as of Q1 2026.
  • Nurix Therapeutics was a new Squarepoint position in Q1 2026.
  • Nurix Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #1770 holding.
  • Squarepoint first reported a position in Nurix Therapeutics in Q1 2021 and has held it in 11 quarters since.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.